CardioTech Announces Patent Filing for Antimicrobial Polymers Designed to Avoid Infections without Using Antibiotic Drugs
Share:
WILMINGTON, Mass., June 18 / / -- CardioTech International, Inc. (AMEX:CTE), a developer and manufacturer of advanced materials and medical devices for the treatment of cardiovascular and other diseases, announced today that it has filed for a US patent on its proprietary antimicrobial formulation of ChronoFlex(R) medical grade polymer and its method of fabrication. These materials are designed to provide a new method for the medical device industry to better control foreign body-derived infections without the use of antibiotic drugs. Cardiotech's antimicrobials can be used in devices as a polymer or a coating.
Commenting on the patent filing, Andrew Reed, Ph.D., CardioTech's Vice President of Science & Technology, said: "With this patent filing, we have introduced a new antimicrobial family of ChronoFlex polymers. Current technology in the marketplace uses antibiotic drugs, which often become depleted in the body and can form antibiotic-resistant bacteria. Moreover, the antimicrobial component of these polymers has been designed to be non-leaching as a result of the polymerization process. Remaining as a component of the polymer is a vital factor for preventing infection."
President & CEO Michael Adams noted that, "Medical device infections cause 70,000 US deaths annually, costing our hospitals an estimated $9 billion. Our antimicrobial polymer technology received a great deal of attention at the Medical Design and Manufacturing -- East conference and exposition last week in New York City. The filing for a new patent reflects the increasing value of CardioTech's intellectual property and builds upon our strategy of developing world class advanced materials."
About CardioTech International:
CardioTech International, Inc. is a medical device company that designs, develops, manufactures and sells innovative products and materials for the treatment of cardiovascular, orthopedic, oncology, urology and other diseases. The Company's business model calls for leveraging its technological and manufacturing expertise in order to expand its royalty and license fee income, develop next generation polymers and manufacture new and complex medical devices. CardioTech is conducting its first clinical trial for regulatory approval in Europe for its CardioPass(TM) synthetic coronary bypass graft. The Company generates revenues from sales of advanced medical devices and materials, as well as from contracted product design and development services. More information about CardioTech is available at its website: http://www.cardiotech-inc.com/.
Source: CardioTech International, Inc.
Web site: http://www.cardiotech-inc.com/
